Formerly operating as Discovery Laboratories (NASDAQ:DIS), Windtree Therapeutics Inc. (NASDAQ:WINT) is a biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications. The company's proprietary KL4 surfactant technology platform involves a synthetic, peptide-containing surfactant that is structurally similar to human pulmonary surfactant. Windtree's technology also involves novel drug-delivery systems that are developed to enable noninvasive administration of aerosolized KL4 surfactant. With this technology initially aimed at improving the management of respitatory distress syndrome (RDS) in premature infants, the company's goal is to eventually utilize its technology to address a variety of respiratory diseases for which there are few or no approved therapies. In december 2018, WindtreePublicly traded respiratory-focused. Windtree Therapeutics Inc. acquired private cardiovascular disease-focused CVie Therapeutics Ltd. in a stock swap.
